What are the efficacy and safety of apixaban compared to warfarin in patients with atrial fibrillation and a history of cancer?
The efficacy and safety of apixaban compared to warfarin in patients with atrial fibrillation and a history of cancer has been studied in several studies. The ARISTOTLE trial found that apixaban was more effective and safer than warfarin in terms of major bleeding events. A 2018 comparative effectiveness study found that direct oral anticoagulants such as apixaban were more effective than warfarin at reducing the risk of stroke or systemic embolism, and were associated with less bleeding. A 2020 network meta-analysis also found that oral anticoagulants such as apixaban were more effective and safer than warfarin in patients with atrial fibrillation and a history of cancer.